Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions

Journal of Virology

Volumn 81, Issue 17, 2007, Pages 9268-9278

  Verity, Erin E ^a,b,c,j   Zotos, Dimitra ^c,d,k   Wilson, Kim ^c   Chatfield, Catherine ^b,l   Lawson, Victoria A ^b,l   Dwyer, Dominic E ^e   Cunningham, Anthony ^e   Learmont, Jennifer ^f   Dyer, Wayne ^f   Sullivan, John ^f   Churchill, Melissa ^b   Wesselingh, Steven L ^b,g   Gabuzda, Dana ^h,i   Gorry, Paul R ^b,g,h   McPhee, Dale A ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d DEAKIN UNIVERSITY   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j CSL LIMITED   (Australia)

^k WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^l UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LONG TERMINAL REPEAT; NEF GENE; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RECIPIENT; VIRUS DETECTION; VIRUS GENE; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANTIBODIES, VIRAL; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; GENE PRODUCTS, NEF; HIV ANTIBODIES; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; PHENOTYPE; SEQUENCE DELETION; VIRAL LOAD; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34548146738     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00650-07     Document Type: Article

References (58)

1. Baba, T. W., Y. S. Jeong, D. Pennick, R. Bronson, M. F. Greene, and R. M. Ruprecht. 1995. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820-1825.
2. Binley, J. M., T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C. J. Petropoulos, and D. R. Burton. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252.
3. Birch, M. R., J. C. Learmont, W. B. Dyer, N. J. Deacon, J. J. Zaunders, N. Saksena, A. L. Cunningham, J. Mills, and J. S. Sullivan. 2001. An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J. Clin. Virol. 22:263-270.
4. Bradney, A. P., S. Scheer, J. M. Crawford, S. P. Buchbinder, and D. C. Montefiori. 1999. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J. Infect. Dis. 179:1264-1267.
5. Brambilla, A., L. Turchetto, A. Gatti, C. Bovolenta, F. Veglia, E. Santagostino, A. Gringeri, M. Clementi, G. Poli, P. Bagnarelli, and E. Vicenzi. 1999. Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. Virology 259:349-368.
6. Carl, S., R. Daniels, A. J. Iafrate, P. Easterbrook, T. C. Greenough, J. Skowronski, and F. Kirchhoff. 2000. Partial "repair" of defective NEF genes in a long-term nonprogressor with human immunodeficiency virus type 1 infection. J. Infect. Dis. 181:132-140.
7. Carotenuto, P., D. Looij, L. Keldermans, F. de Wolf, and J. Goudsmit. 1998. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12:1591-1600.
8. Churchill, M., J. Sterjovski, L. Gray, D. Cowley, C. Chatfield, J. Learmont, J. S. Sullivan, S. M. Crowe, J. Mills, B. J. Brew, S. L. Wesselingh, D. A. McPhee, and P. R. Gorry. 2004. Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J. Infect. Dis. 190:2181-2186.
9. Churchill, M. J., D. I. Rhodes, J. C. Learmont, J. S. Sullivan, S. L. Wesselingh, I. R. Cooke, N. J. Deacon, and P. R. Gorry. 2006. Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J. Virol. 80:1047-1052.
10. Cohen, J. 1997. Novel campaign to test live HIV vaccine. Science 277:1035.
11. Collman, R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L. Kolson, N. Nathanson, and A. Srinivasan. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66:7517-7521.
12. Cranage, M. P., A. M. Whatmore, S. A. Sharpe, N. Cook, N. Polyanskaya, S. Leech, J. D. Smith, E. W. Rud, M. J. Dennis, and G. A. Hall. 1997. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 229:143-154.
13. Deacon, N. J., A. Tsykin, A. Solomon, K. Smith, M. Ludford-Menting, D. J. Hooker, D. A. McPhee, A. L. Greenway, A. Ellett, C. Chatfield, et al. 1995. Genomic structure of an attenuated quasispecies of HIV-1 from a blood transfusion donor and recipients. Science 270:988-991.
14. Dreyer, K., E. G. Kallas, V. Planelles, D. Montefiori, M. P. McDermott, M. S. Hasan, and T. G. Evans. 1999. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res. Hum. Retrovir. 15:1563-1571.
15. D'Souza, M. P., G. Milman, J. A. Bradac, D. McPhee, C. V. Hanson, and R. M. Hendry. 1995. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 9:867-874.
16. Dyer, W. B., G. S. Ogg, M. A. Demoitie, X. Jin, A. F. Geczy, S. L. Rowland-Jones, A. J. McMichael, D. F. Nixon, and J. S. Sullivan. 1999. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J. Virol. 73:436-443.
17. Enose, Y., M. Ui, A. Miyake, H. Suzuki, H. Uesaka, T. Kuwata, J. Kunisawa, H. Kiyono, H. Takahashi, T. Miura, and M. Hayami. 2002. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology 298:306-316.
18. Gendelman, H. E., J. M. Orenstein, M. A. Martin, C. Ferrua, R. Mitra, T. Phipps, L. A. Wahl, H. C. Lane, A. S. Fauci, D. S. Burke, et al. 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167:1428-1441.
19. Gorry, P. R., G. Bristol, J. A. Zack, K. Ritola, R. Swanstrom, C. J. Birch, J. E. Bell, N. Bannert, K. Crawford, H. Wang, D. Schols, E. De Clercq, K. Kunstman, S. M. Wolinsky, and D. Gabuzda. 2001. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J. Virol. 75:10073-10089.
20. Gray, L., M. J. Churchill, N. Keane, J. Sterjovski, A. M. Ellett, D. F. Purcell, P. Poumbourios, C. Kol, B. Wang, N. K. Saksena, S. L. Wesselingh, P. Price, M. French, D. Gabuzda, and P. R. Gorry. 2006. Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5832 allele. J. Virol. 80:3684-3691.
21. Gray, L., J. Sterjovski, M. Churchill, P. Ellery, N. Nasr, S. R. Lewin, S. M. Crowe, S. L. Wesselingh, A. L. Cunningham, and P. R. Gorry. 2005. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 337:384-398.
22. Greenough, T. C., M. Somasundaran, D. B. Brettler, R. M. Hesselton, A. Alimenti, F. Kirchhoff, D. Panicali, and J. L. Sullivan. 1994. Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retrovir. 10:395-403.
23. Hofmann-Lehmann, R., J. Vlasak, A. L. Williams, A. L. Chenine, H. M. McClure, D. C. Anderson, S. O'Neil, and R. M. Ruprecht. 2003. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17:157-166.
24. Igarashi, T., Y. Ami, H. Yamamoto, R. Shibata, T. Kuwata, R. Mukai, K. Shinohara, T. Komatsu, A. Adachi, and M. Hayami. 1997. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine. J. Gen. Virol. 78:985-989.
25. Johnson, R. P., R. L. Glickman, J. Q. Yang, A. Kaur, J. T. Dion, M. J. Mulligan, and R. C. Desrosiers. 1997. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J. Virol. 71:7711-7718.
26. Kestler, H. W., III, D. J. Ringler, K. Mori, D. L. Panicali, P. K. Sehgal, M. D. Daniel, and R. C. Desrosiers. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651-662.
27. Kim, J. H., J. R. Mascola, S. Ratto-Kim, T. C. VanCott, L. Loomis-Price, J. H. Cox, N. L. Michael, L. Jagodzinski, C. Hawkes, D. Mayers, B. L. Gilliam, D. C. Birx, and M. L. Robb. 2001. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res. Hum. Retrovir. 17:1021-1034.
28. Kim, Y. B., M. K. Lee, D. P. Han, and M. W. Cho. 2001. Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain. AIDS Res. Hum. Retrovir. 17:1715-1724.
29. Kimura, T., K. Yoshimura, K. Nishihara, Y. Maeda, S. Matsumi, A. Koito, and S. Matsushita. 2002. Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy. J. Infect. Dis. 185:53-60.
30. Kondo, M., T. Shima, M. Nishizawa, K. Sudo, S. Iwamuro, T. Okabe, Y. Takebe, and M. Imai. 2005. Identification of attenuated variants of HIV-1 circulating recombinant form 01_AE that are associated with slow disease progression due to gross genetic alterations in the nef/long terminal repeat sequences. J. Infect. Dis. 192:56-61.
31. Kumar, A., S. Mukherjee, J. Shen, S. Buch, Z. Li, I. Adany, Z. Liu, W. Zhuge, M. Piatak, Jr., J. Lifson, H. McClure, and O. Narayan. 2002. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. Virology 301:189-205.
32. Learmont, J., B. Tindall, L. Evans, A. Cunningham, P. Cunningham, J. Wells, R. Penny, J. Kaldor, and D. A. Cooper. 1992. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 340:863-867.
33. Learmont, J. C., A. F. Geczy, J. Mills, L. J. Ashton, C. H. Raynes-Greenow, R. J. Garsia, W. B. Dyer, L. McIntyre, R. B. Oelrichs, D. I. Rhodes, N. J. Deacon, and J. S. Sullivan. 1999. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N. Engl. J. Med. 340:1715-1722.
34. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
35. Mariani, R., F. Kirchhoff, T. C. Greenough, J. L. Sullivan, R. C. Desrosiers, and J. Skowronski. 1996. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J. Virol. 70:7752-7764.
36. Mascola, J. R., P. D'Souza, P. Gilbert, B. H. Hahn, N. L. Haigwood, L. Morris, C. J. Petropoulos, V. R. Polonis, M. Sarzotti, and D. C. Montefiori. 2005. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79:10103-10107.
37. McPhee, D., A. Hines, and R. Kiernan. 1993. Inability of polyclonal and monoclonal antibodies to neutralize primary clinical HIV-1 isolates, p. 151-158. In R. A. Lerner, H. Ginsberg, R. M. Chanock and F. Brown (ed.), Vaccines 93. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
38. Montefiori, D. C., T. W. Baba, A. Li, M. Bilska, and R. M. Ruprecht. 1996. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. J. Immunol. 157:5528-5535.
39. Montefiori, D. C., T. S. Hill, H. T. Vo, B. D. Walker, and E. S. Rosenberg. 2001. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J. Virol. 75:10200-10207.
40. Moore, J. P., Y. Cao, J. Leu, L. Qin, B. Korber, and D. D. Ho. 1996. Inter-and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:427-444.
41. Neate, E. V., R. C. Pringle, J. B. Jowett, D. S. Healey, and I. D. Gust. 1987. Isolation of HIV from Australian patients with AIDS, AIDS related conditions and healthy antibody positive individuals. Aust. N. Z. J. Med. 17:461-466.
42. Oelrichs, R. B., V. A. Lawson, K. M. Coates, C. Chatfield, N. J. Deacon, and D. A. McPhee. 2000. Rapid full-length genomic sequencing of two cytopathically heterogeneous Australian primary HIV-1 isolates. J. Biomed. Sci. 7:128-135.
43. Pilgrim, A. K., G. Pantaleo, O. J. Cohen, L. M. Fink, J. Y. Zhou, J. T. Zhou, D. P. Bolognesi, A. S. Fauci, and D. C. Montefiori. 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176:924-932.
44. Qiao, X., B. He, A. Chiu, D. M. Knowles, A. Chadburn, and A. Cerutti. 2006. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat. Immunol. 7:302-310.
45. Rhodes, D., A. Solomon, W. Bolton, J. Wood, J. Sullivan, J. Learmont, and N. Deacon. 1999. Identification of a new recipient in the Sydney Blood Bank Cohort: a long-term HIV type 1-infected seroindeterminate individual. AIDS Res. Hum. Retrovir. 15:1433-1439.
46. Rhodes, D. I., L. Ashton, A. Solomon, A. Carr, D. Cooper, J. Kaldor, N. Deacon, et al. 2000. Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. J. Virol. 74:10581-10588.
47. Salvi, R., A. R. Garbuglia, A. Di Caro, S. Pulciani, F. Montella, and A. Benedetto. 1998. Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J. Virol. 72:3646-3657.
48. Sarmati, L., E. Nicastri, G. el-Sawaf, L. Ventura, A. Salanitro, L. Ercoli, S. Vella, and M. Andreoni. 1997. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment. J. Med. Virol. 53:313-318.
49. Silburn, K. A., D. A. McPhee, A. L. Maerz, P. Poumbourios, R. G. Whittaker, A. Kirkpatrick, W. G. Reilly, M. K. Manthey, and C. C. Curtain. 1998. Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion. AIDS Res. Hum. Retrovir. 14:385-392.
50. Stewart, G. J., L. J. Ashton, R. A. Biti, R. A. Ffrench, B. H. Bennetts, N. R. Newcombe, E. M. Benson, A. Carr, D. A. Cooper, J. M. Kaldor, et al. 1997. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. AIDS 11:1833-1838.
51. Stipp, H. L., A. Kumar, and O. Narayan. 2000. Characterization of immune escape viruses from a macaque immunized with live-virus vaccine and challenged with pathogenic SHIVKU-1. AIDS Res. Hum. Retrovir. 16:1573-1580.
52. Valerie, K., A. Delers, C. Bruck, C. Thiriart, H. Rosenberg, C. Debouck, and M. Rosenberg. 1988. Activation of human immunodeficiency virus type 1 by DNA damage in human cells. Nature 333:78-81.
53. Verity, E. E., L. A. Williams, D. N. Haddad, V. Choy, C. O'Loughlin, C. Chatfield, N. K. Saksena, A. Cunningham, F. Gelder, and D. A. McPhee. 2006. Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody. AIDS 20:505-515.
54. Weis, N., B. O. Lindhardt, G. Kronborg, A. B. Hansen, A. L. Laursen, P. B. Christensen, H. Nielsen, A. Moller, H. T. Sorensen, and N. Obel. 2006. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin. Infect. Dis. 42:1481-1487.
55. Whitney, J. B., and R. M. Ruprecht. 2004. Live attenuated HIV vaccines: pitfalls and prospects. Curr. Opin. Infect. Dis. 17:17-26.
56. Wilson, K. M., E. I. Johnson, H. A. Croom, K. M. Richards, L. Doughty, P. H. Cunningham, B. E. Kemp, B. M. Branson, and E. M. Dax. 2004. Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS 18:2253-2259.
57. Zhang, Y. J., C. Fracasso, J. R. Fiore, A. Bjorndal, G. Angarano, A. Gringeri, and E. M. Fenyo. 1997. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J. Infect. Dis. 176:1180-1187.
58. Zuniga, J., et al. 1997. Setting the record straight: IAPAC's HIV vaccine initiative. J. Int. Assoc. Physicians AIDS Care 3:38-39.